Accelerating Neurodegenerative Clinical Drug Development with AI

Rapid advancements in artificial intelligence (AI) are revolutionizing central nervous system (CNS) clinical trials in neurodegenerative diseases by improving patient recruitment, optimizing study protocols, analyzing data in greater depth and personalizing treatments. These advances not only enable more efficient and accurate clinical trials, but also speed up the development of new treatments and improve patient outcomes.

AI is revolutionizing the landscape of drug discovery and clinical drug development, particularly within central nervous system (CNS) research for neurodegenerative diseases. The emerging importance of AI in neurodegenerative diseases is underscored by the fact that CNS drug development, in general, has higher failure rates than non-CNS drugs, both preclinically and clinically, indicating that more research is required to ensure safety and efficacy in treatments to slow neurodegeneration.

Register for this webinar today to gain insights on how AI is playing a crucial role in advancing CNS research related to neurodegenerative clinical drug development.

Speakers

Anne-Marie Nagy, PhD, Vice President, Head of Internal Medicine & Neuroscience, TFS HealthScience

Anne-Marie Nagy joined TFS in September 2021 to lead the company’s Internal Medicine and Neurosciences Business Units. Her strategic and operational experience from nearly 25 years at both mid-and large-sized pharmaceutical and clinical research organizations has benefited biotech clients throughout their clinical development journey.

She has extensive experience in neuroscience with broad indications such as those in psychiatry (schizophrenia, MDD, bipolar disorders and anxiety) and neurology, including rare and gene therapy (spasticity, cervical dystonia, rare and non-rare epilepsy, Alzheimer’s, Parkinson’s, multiple sclerosis, neuromuscular disorders, Friedreich ataxia and Rett syndrome).

Read more...

Anne-Marie specializes in Internal Medicine indications in women’s health and pulmonary inflammatory diseases (ARDS, asthma, cystic fibrosis, COPD and Covid-19). She possesses drug development and clinical operational expertise across large clinical programs in neurology, psychiatry, pain and cystic fibrosis across all phases in NA, EMEA, South Africa, ASIA PAC and LA, as well as in the peri-post approval drug market. Anne-Marie holds a PhD in Biomedical Sciences from the Faculty of Medicine of the Free University of Brussels, Belgium. She has received numerous academic honors and has several scientific publications in reproductive endocrinology and pulmonary inflammatory diseases.

Read Less...

Message Presenter

Sara Doan, BSc, DC, Executive Director, Program Strategy, Internal Medicine & Neuroscience, TFS HealthScience

Dr. Sara Doan is the Executive Director, Program Strategy and Delivery for Internal Medicine & Neuroscience. She brings a robust 27-year background in global clinical research to her role, with a particular emphasis on psychiatry over the past 12 years. Her expertise spans a broad range of disorders including Alzheimer’s, Parkinson’s, Narcissistic Personality Disorder, Borderline Personality Disorder, Major Depressive Disorder, Post Traumatic Stress Disorder, Bipolar Disorder, Migraine and Anxiety.

Dr. Doan is a Doctor of Chiropractic with a specialization in the central nervous system, having earned her degree from Parker University in Dallas, Texas. She is proficient in both English and Farsi. Dr. Doan demonstrates forward-thinking leadership with a proven track record of success in business operations, coupled with a commitment to excellence in customer management and a strong emphasis on delivering high-level customer service.

Read more...

She takes accountability for developing and executing strategic initiatives, driving development and overseeing operational planning across diverse functions within the organization. With nearly three decades of invaluable experience in the biotech and clinical research organization sectors, she contributes a wealth of knowledge and insights to every project and initiative.

Recognized for her exceptional ability to cultivate and lead high-performing teams, Dr. Doan emphasizes cohesion, morale, open dialogue and a culture of accountability that fosters innovation and collaboration. She possesses extensive expertise in clinical and project management throughout all stages of clinical trials, with a notable record of successfully leading and managing study teams across fully scoped multicenter studies spanning regions, including North and Latin America, Europe, Asia and Australia.

Read Less...

Message Presenter